500 clinical articles and abstracts featuring NovoSorb® technology

Melbourne, Australia – 30 April 2026

PolyNovo Limited (ASX: PNV), a leading medical technology company transforming the management of complex wounds, today announces a key milestone in the maturity of the business, with over 500 clinical articles and abstracts published on NovoSorb® technology.

This reflects a growing and diverse body of independent clinical evidence, that would not be possible without our community of scientists, clinicians, and patients. The milestone includes the publication of an abstract from the CP-003 study, PolyNovo's multicentre, IDE, RCT, sponsored by BARDA (Biomedical Advanced Research and Development Authority).

The pie chart provides an indicative overview of the published clinical evidence to date and may not represent all available publications. Several articles cover multiple indications, which may influence the distribution shown.

Efficacy and safety outcomes are currently being finalised and are expected to be submitted as part of regulatory PMA submission. These findings reflect an ongoing clinical investigation and may not be generalisable to all patient populations or healthcare systems. 

View the abstract: https://doi.org/10.1093/jbcr/irag033.255.

Media contact: [email protected]